Hostname: page-component-74656f9884-kv2lp Total loading time: 0 Render date: 2026-11-05T19:18:19.567Z Has data issue: false hasContentIssue false

4-Nitrobenzaldehyde thiosemicarbazone: a new compound derived from S-(-)-limonene that induces mitochondrial alterations in epimastigotes and trypomastigotes of Trypanosoma cruzi

Published online by Cambridge University Press:  25 February 2015

ELIZANDRA APARECIDA BRITTA
Affiliation:
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
DÉBORA BOTURA SCARIOT
Affiliation:
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
HUGO FALZIROLLI
Affiliation:
Departamento de Química, Universidade Estadual de Maringá, Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
CLEUZA CONCEIÇÃO DA SILVA
Affiliation:
Departamento de Química, Universidade Estadual de Maringá, Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
TÂNIA UEDA-NAKAMURA
Affiliation:
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
BENEDITO PRADO DIAS FILHO
Affiliation:
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
REDOUANE BORSALI
Affiliation:
Univ. Grenoble Alpes, CERMAV-CNRS UPR 5301, F-38000 Grenoble, France
CELSO VATARU NAKAMURA*
Affiliation:
Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil
*
* Corresponding author. Programa de Pós-graduação em Ciências Farmacêuticas, Universidade Estadual de Maringá, PR, Avenida Colombo, 5790, Jd. Universitário, Maringá, Paraná 87020-900, Brazil. E-mail: cvnakamura@uem.br

Summary

Trypanosoma cruzi is the causative agent of Chagas’ disease, a parasitic disease that remains a serious health concern with unsatisfactory treatment. Drugs that are currently used to treat Chagas’ disease are partially effective in the acute phase but ineffective in the chronic phase of the disease. The aim of the present study was to evaluate the antitrypanosomal activity and morphological, ultrastructural and biochemical alterations induced by a new molecule, 4-nitrobenzaldehyde thiosemicarbazone (BZTS), derived from S-(-)-limonene against epimastigote, trypomastigote and intracellular amastigote forms of T. cruzi. BZTS inhibited the growth of epimastigotes (IC50 = 9·2 μ m), intracellular amastigotes (IC50 = 3·23 μ m) and inhibited the viability of trypomastigotes (EC50 = 1·43 μ m). BZTS had a CC50 of 37·45 μ m in LLCMK2 cells. BZTS induced rounding and distortion of the cell body and severely damaged parasite mitochondria, reflected by extensive swelling and disorganization in the inner mitochondrial membrane and the presence of concentric membrane structures inside the organelle. Cytoplasmic vacuolization, endoplasmic reticulum that surrounded organelles, the loss of mitochondrial membrane potential, and increased mitochondrial O2 •ˉ production were also observed. Our results suggest that BZTS alters the ultrastructure and physiology of mitochondria, which could be closely related to parasite death.

Information

Type
Research Article
Copyright
Copyright © Cambridge University Press 2015 
Figure 0

Fig. 1. Inhibition percentage of epimastigote forms of T. cruzi treated with BZTS for 96 h. The data are expressed as the means from three independent experiments.

Figure 1

Fig. 2. Viability inhibition percentage of trypomastigote forms of T. cruzi treated with BZTS for 24 h. The data are expressed as the means from three independent experiments.

Figure 2

Fig. 3. Inhibition percentage of LLCMK2 cells after treatment with BZTS for 96 h. The data are expressed as the means from three independent experiments.

Figure 3

Fig. 4. SEM of T. cruzi. The figure shows control epimastigotes (A) and epimastigotes treated with the IC50 (B, C) and IC90 (D, F) of BZTS. Scale bar = 1 μm.

Figure 4

Fig. 5. TEM of T. cruzi epimastigotes. The figure shows control epimastigotes (A) and epimastigotes treated with the IC50 (B–D) and IC90 (E, I) of BZTS. White arrows indicate mitochondrial swelling. The asterisk indicates cytoplasmic vacuolization. The star indicates membranous structures inside mitochondria. The white arrowhead indicates endoplasmic reticulum surrounding organelles. n, nuclei; m, mitochondrion; k, kinetoplast; r, reservosome. Scale bar = 1 μm.

Figure 5

Fig. 6. Trypanosoma cruzi epimastigotes treated with BZTS and stained with PI. (A) Untreated epimastigotes. (B) Epimastigotes treated with digitonin. (C–E) Epimastigotes treated with BZTS at concentrations of 139 μm (C), 277 μm (D), and 555 μm (E). The percentage of PI-positive cells is shown in the upper-left quadrant.

Figure 6

Fig. 7. Mitochondrial membrane potential assay using flow cytometry and rhodamine 123. (A) Untreated T. cruzi epimastigotes (negative control). (B) Epimastigotes treated with CCCP (positive control). (C–E) Epimastigotes treated with BZTS at concentrations of 139 μm (C), 277 μm (D), and 555 μm (E). FL1-H, rhodamine 123 fluorescence. The decrease percentage of Rh123 fluorescence is shown in the lower-left quadrant and summarized in F.

Figure 7

Fig. 8. Mitochondrial membrane potential assay using flow cytometry and rhodamine 123. (A) Untreated T. cruzi trypomastigotes (negative control). (B) Trypomastigotes treated with CCCP (positive control). (C–E) Trypomastigotes treated with BZTS at concentrations of 27·7 μm (C), 55 μm (D), and 83·2 μm (E). FL1-H, rhodamine 123 fluorescence. The decrease percentage of Rh123 fluorescence is shown in the lower-left quadrant and summarized in F.

Figure 8

Fig. 9. Mitochondrial O2•ˉ production in T. cruzi epimastigotes treated with 55, 139, 277 and 555 μm BZTS for up to 6 h using the fluorescence probe MitoSOX. Antimycin A (10 μm) was used as a positive control. Fluorescence was measured with a VICTOR X3 spectrofluorometer (Perkin-Elmer). The results are expressed as the mean ± s.e. of MitoSOX oxidation (arbitrary units) of at least three independent experiments. *P ≤ 0·05, significant difference from negative control group.

Figure 9

Fig. 10. Mitochondrial O2•ˉ production in T. cruzi trypomastigotes treated with 27·7, 55, 83·2 and 139 μm BZTS for up to 6 h using the fluorescence probe MitoSOX. Antimycin A (10 μm) was used as a positive control. Fluorescence was measured with a VICTOR X3 spectrofluorometer (Perkin-Elmer). The results are expressed as the mean ± s.e. of MitoSOX oxidation (arbitrary units) of at least three independent experiments. *P ≤ 0·05, significant difference from negative control group.